4608 Brompheniramine Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. [PubChem] 86-22-6 6834 C16H19BrN2 < 25 °C 149.5 °C at 5.00E-01 mm Hg Freely soluble (maleate salt) Antihistamines are well absorbed from the gastrointestinal tract after oral administration. Brompheniramine works by acting as an antagonist of the H1 histamine receptors. It also functions as a moderately effective anticholingeric agent, likely an antimuscarinic agent similar to other common antihistamines such as diphenhydramine. Its effects on the cholinergic system may include side-effects such as drowsiness, sedation, dry mouth, dry throat, blurred vision, and increased heart rate. Hepatic (cytochrome P-450 system), some renal. Oral, Rat: LD₅₀ = 318 mg/kg. No indication of carcinogenicity to humans (not listed by IARC). For the treatment of the symptoms of the common cold and allergic rhinitis, such as runny nose, itchy eyes, watery eyes, and sneezing. Signs of overdose include fast or irregular heartbeat, mental or mood changes, tightness in the chest, and unusual tiredness or weakness. 2014-08-30T21:03:45Z 2014-12-24T20:26:52Z Brompheniramine C06857 3183 DB00835 true CN(C)CCC(C1=CC=C(Br)C=C1)C1=CC=CC=N1 C16H19BrN2 InChI=1/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3 InChIKey=ZDIGNSYAACHWNL-UHFFFAOYNA-N 319.239 318.073161265 Exogenous Liquid 3.4 6573 <p>Sperber, N., Papa, D. and Schwenk, E.; US. Patent 2,567,245; September 11, 1951; assigned<br /> to Schering Corporation.<br /> Sperber, N., Papa, D. and Schwenk, E.; U.S. Patent 2,676,964: April 27,1954; assigned to<br /> Schering Corporation.</p>